Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review

BACKGROUND: Osimertinib is the standard of care for patients with non-small-cell lung cancer (NSCLC) patients harboring acquired EGFR T790M resistance mutation. However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakozaki, Taiki, Yomota, Makiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348971/
https://www.ncbi.nlm.nih.gov/pubmed/30774361
http://dx.doi.org/10.2147/OTT.S190034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348971/
https://www.ncbi.nlm.nih.gov/pubmed/30774361
http://dx.doi.org/10.2147/OTT.S190034

Ejemplares similares